| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6742 | 2019 |
| Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... New England Journal of Medicine 381 (17), 1609-1620, 2019 | 2118 | 2019 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1922 | 2022 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ... The lancet Diabetes & endocrinology 7 (10), 776-785, 2019 | 1486 | 2019 |
| Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology NM Hawkins, MC Petrie, PS Jhund, GW Chalmers, FG Dunn, ... European journal of heart failure 11 (2), 130-139, 2009 | 826 | 2009 |
| Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people PS Jhund, K MacIntyre, CR Simpson, JD Lewsey, S Stewart, A Redpath, ... Circulation 119 (4), 515-523, 2009 | 817 | 2009 |
| SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ... The Lancet 400 (10354), 757-767, 2022 | 692 | 2022 |
| Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis … M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, JP Ferreira, ... The Lancet 396 (10244), 121-128, 2020 | 641 | 2020 |
| PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... N Engl J Med 381 (17), 1609-1620, 2019 | 549 | 2019 |
| Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ... Jama 323 (14), 1353-1368, 2020 | 535 | 2020 |
| Declining risk of sudden death in heart failure L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ... New England Journal of Medicine 377 (1), 41-51, 2017 | 529 | 2017 |
| Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ... European journal of heart failure 20 (8), 1230-1239, 2018 | 507 | 2018 |
| Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure K Damman, M Gori, B Claggett, PS Jhund, M Senni, MP Lefkowitz, ... JACC: Heart Failure 6 (6), 489-498, 2018 | 424 | 2018 |
| Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine … SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ... Circulation: Heart Failure 9 (1), e002560, 2016 | 396 | 2016 |
| Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ... Circulation 141 (2), 90-99, 2020 | 394 | 2020 |
| Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF) MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ... Circulation 143 (6), 516-525, 2021 | 391 | 2021 |
| Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF JJV McMurray, AM Jackson, CSP Lam, MM Redfield, IS Anand, J Ge, ... Circulation 141 (5), 338-351, 2020 | 381 | 2020 |
| A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left … JJV McMurray, DL DeMets, SE Inzucchi, L Køber, MN Kosiborod, ... European journal of heart failure 21 (5), 665-675, 2019 | 375 | 2019 |
| Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo … RR Holman, RL Coleman, JCN Chan, JL Chiasson, H Feng, J Ge, ... The lancet Diabetes & endocrinology 5 (11), 877-886, 2017 | 364 | 2017 |
| Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial IS Mackenzie, I Ford, G Nuki, J Hallas, CJ Hawkey, J Webster, SH Ralston, ... The Lancet 396 (10264), 1745-1757, 2020 | 332 | 2020 |
John McMurrayUniversity of Glasgow.E-mailová adresa ověřena na: glasgow.ac.uk